Weiming Li1, Janette N Zara, Ronald K Siu, Min Lee, Tara Aghaloo, Xinli Zhang, Benjamin M Wu, Arthur A Gertzman, Kang Ting, Chia Soo. 1. Los Angeles, Calif.; Harbin, China; and Edison, N.J. From the Dental and Craniofacial Research Institute, the Department of Bioengineering, the Division of Advanced Prosthodontics, Biomaterials, and Hospital Dentistry, and the Department of Orthopedic Surgery, University of California, Los Angeles; the Department of Orthopedics, First Clinical Hospital, Harbin Medical University; and the Musculoskeletal Transplant Foundation.
Abstract
BACKGROUND: Effective regeneration of bone is critical for fracture repair and incorporation and healing of bone grafts used during orthopedic, dental, and craniofacial reconstructions. Nel-like molecule-1 (Nell-1) is a secreted protein identified from prematurely fused cranial sutures of craniosynostosis patients that has been found to specifically stimulate osteogenic cell differentiation and bone formation. To test the in vivo osteoinductive capacity of Nell-1, a critical-sized femoral segmental defect model in athymic rats was used. METHODS: A 6-mm defect, which predictably leads to nonunion if left untreated, was created in the left femur of each rat. Three treatment groups (n = 8 each) were created consisting of rats treated with (1) 1.5 mg/ml Nell-1, (2) 0.6 mg/ml Nell-1, and (3) phosphate-buffered saline only as a Nell-free control. Phosphate-buffered saline or Nell-1 was mixed with demineralized bone matrix as a carrier before implantation. All animals were euthanized 12 weeks after surgery, and bone regeneration was evaluated using radiographic, three-dimensional micro-computed tomographic, and histologic analysis. RESULTS: Both Nell-1-treated groups had significantly greater bone formation compared with the Nell-free group, with bone volume increasing with increasing Nell-1 concentration. CONCLUSIONS: Nell-1 in a demineralized bone matrix carrier can significantly improve bone regeneration in a critical-sized femoral segmental defect in a dose-dependent manner. The results of this study demonstrate that Nell-1 is a potent osteospecific growth factor that warrants further investigation. Results also support the potential application of Nell-1 as a bone graft substitute in multiple clinical scenarios involving repair of critical bone loss when autograft bone is limited or unavailable.
BACKGROUND: Effective regeneration of bone is critical for fracture repair and incorporation and healing of bone grafts used during orthopedic, dental, and craniofacial reconstructions. Nel-like molecule-1 (Nell-1) is a secreted protein identified from prematurely fused cranial sutures of craniosynostosispatients that has been found to specifically stimulate osteogenic cell differentiation and bone formation. To test the in vivo osteoinductive capacity of Nell-1, a critical-sized femoral segmental defect model in athymic rats was used. METHODS: A 6-mm defect, which predictably leads to nonunion if left untreated, was created in the left femur of each rat. Three treatment groups (n = 8 each) were created consisting of rats treated with (1) 1.5 mg/ml Nell-1, (2) 0.6 mg/ml Nell-1, and (3) phosphate-buffered saline only as a Nell-free control. Phosphate-buffered saline or Nell-1 was mixed with demineralized bone matrix as a carrier before implantation. All animals were euthanized 12 weeks after surgery, and bone regeneration was evaluated using radiographic, three-dimensional micro-computed tomographic, and histologic analysis. RESULTS: Both Nell-1-treated groups had significantly greater bone formation compared with the Nell-free group, with bone volume increasing with increasing Nell-1 concentration. CONCLUSIONS:Nell-1 in a demineralized bone matrix carrier can significantly improve bone regeneration in a critical-sized femoral segmental defect in a dose-dependent manner. The results of this study demonstrate that Nell-1 is a potent osteospecific growth factor that warrants further investigation. Results also support the potential application of Nell-1 as a bone graft substitute in multiple clinical scenarios involving repair of critical bone loss when autograft bone is limited or unavailable.
Authors: Aaron W James; Jia Shen; Rebecca Tsuei; Alan Nguyen; Kevork Khadarian; Carolyn A Meyers; Hsin Chuan Pan; Weiming Li; Jin H Kwak; Greg Asatrian; Cymbeline T Culiat; Min Lee; Kang Ting; Xinli Zhang; Chia Soo Journal: JCI Insight Date: 2017-06-15
Authors: Aaron W James; Angel Pan; Michael Chiang; Janette N Zara; Xinli Zhang; Kang Ting; Chia Soo Journal: Biochem Biophys Res Commun Date: 2011-06-23 Impact factor: 3.575
Authors: Aaron W James; Shen Pang; Asal Askarinam; Mirko Corselli; Janette N Zara; Raghav Goyal; Le Chang; Angel Pan; Jia Shen; Wei Yuan; David Stoker; Xinli Zhang; John S Adams; Kang Ting; Chia Soo Journal: Stem Cells Dev Date: 2012-02-22 Impact factor: 3.272
Authors: Ronald K Siu; Janette N Zara; Yaping Hou; Aaron W James; Jinny Kwak; Xinli Zhang; Kang Ting; Benjamin M Wu; Chia Soo; Min Lee Journal: Tissue Eng Part A Date: 2011-10-11 Impact factor: 3.845
Authors: Jia Shen; Aaron W James; Xinli Zhang; Shen Pang; Janette N Zara; Greg Asatrian; Michael Chiang; Min Lee; Kevork Khadarian; Alan Nguyen; Kevin S Lee; Ronald K Siu; Sotirios Tetradis; Kang Ting; Chia Soo Journal: Am J Pathol Date: 2016-01-06 Impact factor: 4.307
Authors: Asal Askarinam; Aaron W James; Janette N Zara; Raghav Goyal; Mirko Corselli; Angel Pan; Pei Liang; Le Chang; Todd Rackohn; David Stoker; Xinli Zhang; Kang Ting; Bruno Péault; Chia Soo Journal: Tissue Eng Part A Date: 2013-04-04 Impact factor: 3.845